Answers are grounded in this paper and cite their sources.
New post hoc analysis of IPF clinical trials suggests that treatment with pirfenidone slows the worsening of patient-reported breathlessness over 12 months versus placebo in patients with more advanced disease (GAP stage II/III or FVC <80%)http://bit.ly/2yJyUVT
No takes yet. Share an insight, caveat, or question.
Glassberg et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: